Linked Life Data

21459795

Source:http://linkedlifedata.com/resource/pubmed/id/21459795

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2011-7-1
pubmed:databankReference
pubmed:abstractText
Background Allogeneic hematopoietic cell transplantation is considered the preferred post-remission therapy in patients with acute myeloid leukemia cytogenetically defined as being at high risk. To substantiate evidence for allogeneic hematopoietic cell transplantation in first complete remission in these high-risk patients we performed a landmark analysis within a single prospective multicenter treatment trial. DESIGN AND METHODS: By the time of analysis, 2,347 patients had been accrued into the AMLCG 99 trial between 1999 - 2007. Out of this population, 243 patients under 60 years old fulfilled the criteria for high-risk cytogenetics. Landmark analyses were performed with a control cohort, who remained in first complete remission at least the median time from complete remission to transplantation in the intervention group. RESULTS: After standardized induction therapy, 111 patients under 60 years old achieved complete remission. A matched allogeneic donor was identified for 59 patients (30 sibling donors, 29 unrelated donors). Fifty-five patients received an allogeneic hematopoietic cell transplant after a median time of 88 days in first complete remission. Of the remaining 56 patients, 21 relapsed within 90 days after achieving first complete remission and for 7 patients with relevant comorbidities no donors search was initiated, leaving 28 patients given conventional post-remission therapy as the control cohort. The median follow-up of surviving patients was 60.4 months. Patients with an allogeneic donor had substantially better 5-year overall and relapse-free survival rates than the control group (48% versus 18%, P=0.004 and 39% versus 10%, P<0.001, respectively). A survival benefit from transplantation was evident regardless of donor type, age and monosomal karyotype. Conclusions Beyond evidence available for subgroups of high-risk patients, the findings of this study establish in a broader manner that allogeneic hematopoietic cell transplantation is a preferable consolidation treatment for patients with acute myeloid leukemia and high-risk cytogenetics. The study was registered at Clinicaltrials.gov as NCT00266136.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-11110676, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-12036858, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-12393746, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-15010150, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-15377469, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-15632409, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16020510, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16110027, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16482208, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16516130, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16597592, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-16735702, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-17213292, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-17336256, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-17785583, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-18450602, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-18455284, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-18768435, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19047294, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19151786, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19380453, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19450761, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19509382, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-19880497, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-20558611, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-20562328, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-20805454, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-6245359, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-6338977, http://linkedlifedata.com/resource/pubmed/commentcorrection/21459795-9746770
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1592-8721
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
96
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
972-9
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trial.
pubmed:affiliation
Department of Medicine A/Hematology and Oncology, University of Muenster, Albert-Schweitzer-Str. 33, D-48129 Muenster, Germany. stell-jes@uni-muenster.de
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study